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Abstract
Phagocytosis and inflammation within the lungs is crucial for host defense during bacterial pneumonia. Triggering receptor
expressed on myeloid cells (TREM)-2 was proposed to negatively regulate TLR-mediated responses and enhance
phagocytosis by macrophages, but the role of TREM-2 in respiratory tract infections is unknown. Here, we established the
presence of TREM-2 on alveolar macrophages (AM) and explored the function of TREM-2 in the innate immune response to
pneumococcal infection in vivo. Unexpectedly, we found Trem-22/2 AM to display augmented bacterial phagocytosis in
vitro and in vivo compared to WT AM. Mechanistically, we detected that in the absence of TREM-2, pulmonary macrophages
selectively produced elevated complement component 1q (C1q) levels. We found that these increased C1q levels depended
on peroxisome proliferator-activated receptor-d (PPAR-d) activity and were responsible for the enhanced phagocytosis of
bacteria. Upon infection with S. pneumoniae, Trem-22/2 mice exhibited an augmented bacterial clearance from lungs,
decreased bacteremia and improved survival compared to their WT counterparts. This work is the first to disclose a role for
TREM-2 in clinically relevant respiratory tract infections and demonstrates a previously unknown link between TREM-2 and
opsonin production within the lungs.
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Introduction
Phagocytosis is the process by which cells ingest particles and is
a major effector mechanism of the innate immune system.
Professional phagocytes such as macrophages use a variety of
surface receptors including scavenger-, Fc- and opsonin-receptors
to internalize microbes. In addition, innate immune receptors such
as Toll like receptors (TLRs) recognize conserved microbial
structures and trigger the production of pro-inflammatory
cytokines and chemokines, thereby shaping both the innate and
adaptive immune response.
TLR activation and phagocytosis are intimately linked. Upon
phagocytosis of Gram positive and negative bacteria, TLR2 and 4
initially located at the plasma membrane accumulate into
phagosomes, sample their contents and elicit immune responses
to products which only become accessible after digestion of the cell
wall of bacteria [1,2,3]. TLR activation also enhances the
expression of phagocytic receptors such as scavenger receptor A
or MARCO and elevates opsonin levels [4,5,6,7]. The prime aim
of such inflammatory phagocytosis is to urgently remove invading
pathogens before they multiply, invade other tissues and spread
systemically. The rapid elimination of pathogens thus prevents
excessive inflammation that can otherwise result in immunopa-
thology and organ failure. Understanding the mechanisms that
control phagocytosis and limit inflammation is important as this
has implications in the survival from infectious diseases. The
triggering receptor expressed on myeloid cells 2 (TREM-2) has
been proposed to regulate both processes.
TREM-2 belongs to a conserved but functionally distinct gene
family of proteins, with the best studied family members including
TREM-1 and 2 [8,9]. TREM-2 is a receptor with an unknown
ligand and is expressed by several cell types including bone marrow
derived macrophages (BMDM), microglia and osteoclasts [10,11,12].
Humans with mutations in TREM-2 develop Nasu-Hakola disease,
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which is characterized by progressive dementia and bone cysts
[12,13]. Furthermore, recent evidence shows individuals who possess
heterozygous rare variants of TREM-2 are at increased risk of
Alzheimer’s disease [14,15]. TREM-2 signals via the immunor-
eceptor tyrosine-based activation motif (ITAM) of the adaptor
protein DNAX activation protein of 12 kDa (DAP-12) to mediate its
downstream effects. DAP-12 is rather promiscuous and is used by
many other receptors having both activating and inhibitory functions
[16]. When TREM-1 is engaged, it potentiates the immune response
to bacteria and TLR ligands [17,18,19]. Conversely, TREM-2 was
reported to function as a negative regulator of TLR mediated
inflammation [10,11,20]. Therefore, TREM family members act as
fine tuners of TLRmediated innate immune responses. Significantly,
TREM-2 also plays an important role in phagocytosis. Over-
expression of TREM-2 in Chinese hamster ovary (CHO) cells
confers binding of both Staphylococcus aureus and Escherichia coli and
TREM-2 mediates phagocytosis of E. coli in BMDM [21]. The in
vivo relevance of the phagocytic capacity of TREM-2 in relation to
E. coli peritonitis has been corroborated by a recent study showing
that administration of bone marrow cells that over-express TREM-2
enhances bacterial clearance and improves survival in a cecal ligation
and puncture (CLP) model [22].
In this report we examine the function of TREM-2 in the
context of Streptococcus pneumoniae infection, the most frequent cause
of community acquired pneumonia [23]. We chose to examine
TREM-2 in this context for several reasons. Firstly, TREM-2 is
expressed on human AM as well as mouse bronchial epithelial
cells, suggesting a role for TREM-2 within the pulmonary
compartment [24,25]. Secondly, pulmonary expression of
TREM-2 and DAP-12 increases in mice following Mycobacterium
bovis infection [26], but the functional importance of TREM-2 in
lung host defense is unknown. Lastly, both the early innate
immune response and phagocytosis are critical for the outcome
during pneumococcal pneumonia [27,28,29,30]. Thus, we hy-
pothesized that studying TREM-2 in the context of pneumococcal
pneumonia would provide an ideal model system for examining
the cross-talk between TLR signaling and phagocytosis within the
lungs.
Results
Pulmonary TREM-2 expression and function during early
pneumococcal pneumonia
To investigate the role of pulmonary TREM-2 in the context of
bacterial pneumonia, we first established which cell types
expressed TREM-2 within the lungs. We determined TREM
transcript levels in primary AM and respiratory epithelial lung
cells (pEC) as well as epithelial cell lines such as alveolar MLE-12
and bronchial MLE-15 cells, respectively [31], and included RAW
264.7 macrophages as a positive control [32,33]. While TREM-1
expression was predominantly restricted to macrophages, we
discovered TREM-2 to be strongly expressed in both AM and
respiratory epithelial cells (Fig. 1A). We confirmed these results by
demonstrating expression of TREM-2 on primary AM using
western blot (Fig. 1B). Interestingly, we detected two bands in
AM, with the upper band probably corresponding to a glycosy-
lated form of TREM-2 as previously observed [34]. Specificity for
the antibody was provided as minimal detection of TREM-2 was
observed in TREM-2 deficient AM. We then sought to determine
pulmonary TREM-2 expression upon S. pneumoniae infection and
found a time dependent upregulation in whole lung transcript
levels, with highest expression 48 h post infection (Fig. 1C). This
increase in pulmonary TREM-2 expression during infection most
likely reflected the influx of TREM-2 expressing cells, since
TREM-2 transcript levels on primary AM declined following S.
pneumoniae treatment (Fig. 1D). Together, TREM-2 was abun-
dantly expressed within healthy lungs and further induced upon
infection with S. pneumoniae.
To exploit the functional role of this constitutive pulmonary
TREM-2 expression in relation to early pulmonary inflammatory
responses following bacterial infection, we next infected WT and
Trem-22/2 mice with S. pneumoniae for 6 h. Much to our surprise,
since TREM-2 was earlier considered a negative regulator of
inflammation [10,20], we did not identify any differences in levels
of several inflammatory mediators tested, such as TNF-a, MCP-1,
IL-1b and IL-6 (Fig. 1E and F). In fact Trem-22/2 mice only
displayed elevated levels of KC, a chemokine required for
neutrophil influx following bacterial respiratory tract infections
[35] (Fig. 1E and F). This was accompanied by a modest increase
in recruited neutrophils (Fig. 1G). Altogether, these data
demonstrate that lung TREM-2 only partially dampened inflam-
mation following S. pneumoniae infection in vivo.
Decreased TLR2 mediated cytokine production in TREM-2
deficient AM
Given that TREM-2 is considered a negative regulator of
inflammation, our observation of unaltered cytokine release in
lungs of Trem-22/2 mice following S. pneumoniae infection was
surprising. We therefore first re-examined the regulatory function
of TREM-2 and concentrated on macrophage responses to
bacteria. We found S. pneumoniae or LPS induced TNF-a and
KC synthesis by Trem22/2 BMDM augmented (Fig. 2A and B),
supporting previous observations of TREM-2 negatively regulat-
ing TLR mediated cytokine synthesis [10].
Getting back to the specific role of TREM-2 within the lungs,
we then determined whether Trem-22/2 AM would behave
similarly to BMDM in response to S. pneumoniae or its lipotechoic
acid (LTA), a known TLR2 ligand [36]. Strikingly, Trem-22/2 AM
displayed opposite effects to Trem-22/2 BMDM. We discovered
that TREM-2 deficient AM exhibited decreased inflammation in
Author Summary
Bacterial respiratory tract infections are a major cause of
morbidity and mortality, and Streptococcus pneumoniae (S.
pneumoniae) remains the main cause of community
acquired pneumonia worldwide. The continued rise in
antibiotic resistance stresses the need for better insights
into the host defense mechanisms associated with
pneumococcal pneumonia. The early innate immune
response that constitutes bacterial phagocytosis, comple-
ment activation and inflammation is critical for the
outcome during pneumonia. The triggering receptor
expressed on myeloid cells 2 (TREM-2) has recently been
shown to be both a negative regulator of the inflammatory
response and a promoter of phagocytosis, but its
contribution to pneumonia remains unknown. In our
study, we unexpectedly found that alveolar macrophage
expressed TREM-2 is detrimental in bacterial phagocytosis
and clearance during pneumococcal pneumonia. This
occurred via the suppressive effects of TREM-2 on
complement component 1q (C1q), an important regulator
of bacterial phagocytosis that is crucial for the host
response during pneumonia. Thus, targeting the TREM-2
pathway could be used as a novel strategy for modulating
C1q production and pulmonary innate immune responses,
which could be of clinical relevance during pneumonia
and other respiratory tract infections.
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response to either stimuli (Fig. 2C and D). The mechanism
whereby ITAM coupled receptors generate inhibitory or activat-
ing signals is not well understood. However, the avidity of receptor
ligation and thus ligand density has been described as a potential
reason for pro- versus anti-inflammatory responses by ITAM
associated receptors [16,37]. To rule out that the dose of bacteria
could alter the effect of TREM-2 on TLR signaling, we stimulated
primary AM from WT and Trem-22/2 mice with increasing doses
of S. pneumoniae. While TNF- a and KC release was not different
between WT and Trem-22/2 AM at an MOI of 25, synthesis was
significantly lower in Trem-22/2 AM stimulated with an MOI of
100 S. pneumoniae (Fig. 2E and F). These data suggest that
TREM-2 regulated TLR2 mediated cytokine synthesis in a cell
type specific manner, i.e. it diminished inflammation in BMDM,
but partially enhanced it in AM. Furthermore, given that BMDM
and AM were stimulated with an identical dose of bacteria, these
data indicate that the cell type specific effects of TREM-2 cannot
be explained by differences in receptor ligation and avidity.
Increased phagocytic activity in TREM-2 deficient alveolar
macrophages in vitro and in vivo
Considering that the elimination of pathogens is the crucial step
in host defense during pneumonia, we then more closely examined
the anti-bacterial properties of macrophages and the role of
TREM-2 herein. In agreement with published reports that
indicated TREM-2 to be a phagocytic receptor for E. coli [21]
we first identified that Trem-22/2 BMDM exhibited a decreased
uptake of S. pneumoniae compared to WT cells (Fig. 3A). Although
we anticipated that Trem-22/2 AM would behave similarly, this
postulate proved to be incorrect as Trem-22/2 AM surprisingly
exhibited an enhanced uptake of S. pneumoniae compared to WT
AM (Fig. 3B). We could rule out differences in phagocytosis
between the cell-types due to the kind of bacterium used, since
uptake of E. coli was equally enhanced in Trem-22/2 AM
compared to WT AM (Fig. 3C). We further confirmed the
enhanced uptake of S. pneumoniae in Trem-22/2 AM using confocal
microscopy (Fig. 3D and Fig. S1) and corroborated previously
published observations showing that Trem-22/2 BMDM exhibit
decreased uptake of E. coli compared to WT BMDM [21] (Fig.
S2). Increased phagocytosis of S. pneumoniae by TREM-2 deficient
AM was also found following opsonisation of bacteria with either
pneumococcal serotype 3 capsular antibodies or 10% WT serum,
indicating that TREM-2 can inhibit both FcR-dependent and
independent phagocytosis of S. pneumoniae (Fig. 3E and F).
Uptake of FITC labeled BSA was unchanged between the
genotypes of AM, while in the same experiment uptake of S.
pneumoniae was significantly higher, thus illustrating that TREM-2
affects phagocytosis of bacteria but not endocytosis of BSA
(Fig. 3G). Further, to extend these studies to other serotypes of S.
pneumoniae, we tested uptake of serotype 19A S. pneumoniae, a
common serotype that causes invasive pneumococcal disease in
children [38]. By doing so, we could observe enhanced uptake of
19A S. pneumoniae in Trem-22/2 AM compared to their WT
counterparts (Fig. 3H).
Figure 1. Pulmonary TREM-2 expression and function during S. pneumoniae induced inflammation. (A) TREM-1 and TREM-2 expression
was evaluated in the indicated cell types using RT-PCR. (B) Western blot was used to evaluate TREM-2 expression on AM. (C) WT mice (n = 6 per time
point) were intranasally inoculated with 105 CFU S. pneumoniae and after indicated time points TREM-2 lung transcript levels were evaluated. (D) WT
AM were treated with 26107 CFU/ml S. pneumoniae for indicated time points and TREM-2 RT-PCR was conducted. (E–G) WT and Trem-22/2 mice
(n = 7 per genotype) were intranasally infected with 105 CFU S. pneumoniae for 6 h and levels of indicated cytokines were evaluated in the lung (E) or
BALF (F) and neutrophil counts were determined in the BALF (G). Data represent mean 6 SEM and are (A–G) representative of two independent
experiments. Differences were calculated versus time point 0 (C–D) or versus WT (E–G) and are indicated as * p,0.05, ** p,0.005, **** p,0.0001.
doi:10.1371/journal.ppat.1004167.g001
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We next set out to investigate if the enhanced phagocytosis of S.
pneumoniae by TREM-2 deficient AM would also be observed in
vivo. To this end, we inoculated WT and Trem-22/2 mice with
FITC-labeled S. pneumoniae and assessed the uptake of S. pneumoniae
by phagocytes in vivo using flow cytometry. By doing so, we could
verify that Trem-22/2 F4/80+ CD11c+ AM did indeed display
augmented bacterial phagocytosis in vivo compared to their WT
counterparts (Fig. 3I and J). Considering the importance of
infiltrating neutrophils in phagocytosing bacteria during pneumo-
nia, we then examined the potential contribution of neutrophils to
bacterial clearance in vivo. Following intranasal infection with
FITC labeled S. pneumoniae, we found a tendency for decreased
phagocytosis by Ly6G+CD11b+ lung neutrophils from Trem-22/2
mice compared to their WT counterparts, suggesting that the
Figure 2. Cell type specific effects of TREM-2 on S. pneumoniae and TLR2 mediated cytokine production. (A–B) WT and Trem-22/2
BMDM (n= 4 per genotype) were treated with 26107 CFU/ml S. pneumoniae or 100 ng/ml LPS for 6 h and TNF-a (A) or KC (B) levels were measured
in the supernatant. (C–D) WT and Trem-22/2 AM (n= 4 per genotype/time point) were treated with 26107 CFU/ml S. pneumoniae (C) or 10 mg/ml S.
pneumoniae LTA (D) for the indicated times and KC and TNF-a levels were measured in the supernatant. (E–F) WT and Trem-22/2 AM (n= 4 per
genotype/MOI) were treated with the indicated doses of S. pneumoniae and TNF-a (E) and KC (F) levels were determined in the supernatant.
Statistical comparisons are done versus WT cells (A–B) at a given timepoint (C–D), or at a particular MOI of S. pneumoniae (E–F), and indicated as: *
p,0.05, ** p,0.005, *** p,0.001, **** p=,0.0001. All data represent mean 6 SEM and are representative of two independent experiments.
doi:10.1371/journal.ppat.1004167.g002
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Figure 3. Elevated phagocytosis of bacteria by TREM-2 deficient AM. (A) WT and Trem-22/2 BMDM (n= 4–5 per genotype) were incubated
with FITC labeled S. pneumoniae (MOI 100) and after 1 h phagocytosis was assessed using FACS. (B–C) WT and Trem-22/2 AM (n= 4 per genotype)
were incubated with FITC labeled S. pneumoniae (B) or E. coli (C) (MOI of 100) and phagocytosis was assessed using FACS 1 h later. (D) Elevated
phagocytosis of S. pneumoniae by Trem-22/2 AM as determined using confocal microscopy as described in the M&M section. The percentage of cells
that contain bacteria is depicted (n = 4–5 per genotype). (E–F) WT and Trem-22/2 AM (n= 4–5 per genotype) were incubated with FITC labeled S.
pneumoniae (MOI 100) under either serum free conditions (SFM) or the bacteria were pre-opsonised with 10% anti-pneumococcal serotype III
capsular antibody (ST3-Ab) (E) or 10% pooled WT mouse serum (F) for 30 min before addition to the cells. Phagocytosis was assessed 1 h later. (G)
WT and Trem-22/2 AM (n= 4 per genotype) were incubated with 1 mg/ml FITC labeled BSA or FITC labeled S. pneumoniae (MOI 100) and phagocytosis
The Role of TREM-2 in Pneumococcal Pneumonia
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modest increase in neutrophil numbers early during infection
(Fig. 1G) was not responsible for the improved bacterial clearance
of Trem-22/2 mice (Fig. 3K and L). We finally asked if the
enhanced phagocytosis by Trem-22/2 AM would result in an
improved bacterial clearance during pneumococcal pneumonia in
vivo. We infected mice with S. pneumoniae for 24 h and recovered
significantly fewer bacteria from lungs and bronchoalveolar lavage
fluid (BALF) from Trem-22/2 mice (Fig. 3M).
These data were surprising and important because they
challenged the general view of TREM-2 acting as a phagocytic
receptor and negative regulator of inflammation but suggested that
TREM-2 can modulate phagocytosis and inflammation in a very
cell-type specific manner. With uptake of bacteria being higher in
resident AM from TREM-2 deficient mice, this macrophage type
obviously displays opposite effects from BMDM.
Increased C1q production via PPAR-d in TREM-2-deficient
alveolar macrophages
Given the importance of lung macrophages in pneumococcal
clearance [29,39], we next focused on determining the molecular
targets by which TREM-2 deficiency in AM was able to influence
pneumococcal uptake and we conducted a genome wide
transcriptome analysis of both genotypes of AM. While we
discovered no difference in the expression levels of important
phagocytic receptors such as the scavenger receptors Cd36, Marco,
Sra-1 and Lox-1 and the complement receptors Cr1 (Cd35) and Cr3
(itgb2/itgam; Cd11b/Cd18) (Fig. 4A and Fig. S3), we importantly
found that Trem-22/2 AM expressed higher baseline levels of
opsonins such as C1qa, C1qb, C1qc and Thbs1 (encoding
thrombospodin; Fig. 4A). We confirmed higher basal C1qb and
Thbs1 levels in TREM-2 deficient AMs by RT-PCR (Fig. 4B) and
verified enhanced intracellular C1q protein levels in Trem-22/2
AM by flow cytometry (Fig. 4C). In search for specific factors that
would explain differences in TREM-2 mediated responses
between AM and BMDM, we found that C1qb levels were
exclusively increased in Trem22/2 AM, whereas Thbs1 levels were
elevated in both TREM-2 deficient AM and BMDM (Fig. 4D).
This led us to hypothesize that altered C1q expression could
account for differential phagocytic effects between AM and
BMDM.
As microarray data suggested that TREM-2 had the ability to
influence basal C1q production in AM, we decided to test this idea
and to determine C1qb and C1qc transcript levels in RAW264.7
macrophages over-expressing TREM-2. Over-expression of
TREM-2 was able to lower basal C1qb and C1qc transcript levels,
proving that TREM-2 had the ability to regulate C1q transcrip-
tion (Fig. 4E and Fig. S4). The nuclear receptor peroxisome
proliferator-activated receptor-d (PPAR-d) has previously been
shown to regulate C1q and the C1q promoter contains binding
sites for this transcription factor [40]. To understand the potential
role of PPAR-d in our cell system, we treated Trem-22/2 AM with
the PPAR-d inhibitor GSK0660 [41] and could revert C1qb
transcript levels to those of WT AM in a dose dependent manner
(Fig. 4F). We observed similar results using another PPAR-d
inhibitor, arguing against inhibitor-specific effects in down
regulating C1q expression (Fig. S5). Specificity of these
compounds for PPAR-d and not other PPARs such as PPAR-c
was evaluated, since activation of PPAR-d with the PPAR-d
activator GW0742 [40] increased transcript levels of C1qb and
C1qc in WT AM in a dose dependent manner and co-incubation
with PPAR-d inhibitors abrogated this increase (Fig. S5). These
data confirmed that PPAR-d activity determines C1q transcription
in AM. There was no striking difference in transcript and total
protein levels of PPAR-d between WT and Trem-22/2 AM,
suggesting that the ability of TREM-2 to regulate C1q via PPAR-d
was not due to enhanced PPAR-d levels (Fig. S6). To demonstrate
that TREM-2 itself downregulates PPAR-d activity, we made use
of TREM-2 over-expressing HEK cells and quantified PPAR-d
activation using a reporter system. Over-expression of TREM-2
was able to lower both basal and ligand-induced PPAR-d reporter
activity (Fig. 4G). To rule out differences between HEK cells and
macrophages, and to further confirm the reporter gene experi-
ments, we next stimulated TREM-2 or GFP control over-
expressing RAW264.7 macrophages with GW0742 or DMSO
control and monitored nuclear PPAR-d levels. These data
corroborated the experiments in Fig. 4G and demonstrated that
TREM-2 could suppress PPAR-d activity in RAW264.7 macro-
phages (Fig. 4H). To understand the specific effect of TREM-2 on
PPAR-d activation in AM, we next monitored nuclear and
cytoplasmic levels of PPAR-d in WT and Trem-22/2 AM following
GW0742 treatment. Trem-22/2 AM exhibited an early transloca-
tion of ligand-induced PPAR-d from the cytoplasm to the nucleus,
compared to their WT counterparts (Fig. 4I).
Altogether, these data demonstrate that TREM-2 can suppress
basal levels of C1q and suggest that the elevated C1q production
observed in Trem-22/2 AM occurs via effects of TREM-2 on the
nuclear receptor PPAR-d, a known activator of C1q transcription
[40].
Elevated S. pneumoniae phagocytosis and bacterial
clearance in TREM-2 deficient AM and mice is dependent
on C1q
C1q is unique among the complement factors, as it is exclusively
produced by macrophages and not hepatocytes [42,43,44,45,46].
While C1q is well-known for its role in initiating the classical
complement pathway, it also exerts complement-independent
functions such as clearance of immune-complexes or apoptotic
cells [47,48,49]. The importance of complement in general,
including C1q, in protecting against pneumococcal infections is
well established [30,50] and has been based on the importance of
C3b-mediated opsonization of bacteria. Since we observed that
TREM-2 deficient AM produced more C1q (Fig. 4A, B, C and
F) and that Trem-22/2 mice showed a modestly elevated
neutrophil influx early during pneumococcal pneumonia
(Fig. 1G), we speculated that classical complement activation
could be increased in the pulmonary compartment of Trem-22/2
mice following S. pneumoniae infection and monitored levels of C3a
and C5a, anaphylatoxins, which promote neutrophil influx [51].
However, we did not observe any differences in C3a and C5a in
the BALF of Trem-22/2 mice both 6 h and 24 h post S. pneumoniae
was assessed 1 h later by FACS. (H) WT and Trem-22/2 AM (n= 4 per genotype) were incubated with FITC labeled S. pneumoniae strain 19A (MOI 100)
and phagocytosis was assessed 1 h later by FACS. (I–L) WT and Trem-22/2 mice (n = 7 mice per genotype) were intranasally infected with 106 CFU
FITC labeled S. pneumoniae for 4 h and in vivo phagocytosis by AM (I–J) and neutrophils (K–L) was determined. J and L show representative FACS
plots of data in I and K. (M) WT and Trem-22/2 mice (n = 6 mice per genotype) were intranasally infected with 105 CFU S. pneumoniae and bacterial
CFUs were enumerated 24 h post infection in the lung and BALF. All data represent mean6 SEM versus WT unless otherwise indicated. Data in (A–C,
F and H) are representative of three independent experiments and all other data are representative of two independent experiments. * p,0.05, **
p,0.005, **** p,0.0001.
doi:10.1371/journal.ppat.1004167.g003
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Figure 4. Elevated C1q production via PPAR-d in TREM-2 deficient AM. (A) Heat map from microarray data depicting baseline expression of
selected genes in WT and Trem-22/2 AMs. (B) Verification of enhanced basal expression of the opsonins C1qb and Thbs1 in AM using RT-PCR (n = 4
per genotype). (C) Basal expression of C1qb in WT versus Trem-22/2 AMs as determined by intracellular FACS. Green line depicts WT macrophages,
pink Trem-22/2 macrophages and black represents isotype control antibody. (D) C1qb and Thbs1 basal expression was determined in WT and Trem-
22/2 BMDM (n= 4 per genotype) using RT-PCR. (E) C1qb expression was quantified in RAW264.7 cells over-expressing TREM-2 or GFP control (n = 4
per condition). (F) WT and Trem-22/2 AM (n = 4 per genotype/condition) were pre-treated for 24 h with the indicated doses of the PPAR-d inhibitor
GSK0660 or DMSO control after which RT-PCR of C1qb was performed. (G) HEK cells were transfected with a PPRE reporter plasmid together with
TREM-2 and DAP-12 or a vector control, stimulated with 1 mM of the PPAR-d activator GW0742 or DMSO 24 h post transfection, and luciferase activity
was assayed 48 h post transfection (n = 4 per condition). (H) RAW264.7 cells over-expressing TREM-2 or GFP control (n = 4 per condition), were
treated with 1 mM of the PPAR-d activator GW0742 or DMSO control for 24 h, nuclear extracts were prepared and PPAR-d activity levels were
monitored as described in the methods. (I) WT and Trem-22/2 AM were treated with 1 mM of the PPAR-d activator GW0742 or DMSO control for the
indicated time points, nuclear and cytoplasmic extracts were prepared and blotted for PPAR-d. All data are representative of two independent
experiments except for data in (E), which is representative of three independent experiments, and represent mean 6 SEM versus WT (B and D), GFP
control cells (E), DMSO (F) or vector (G). * p,0.05, ** p,0.005, *** p,0.001, **** p,0.0001.
doi:10.1371/journal.ppat.1004167.g004
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infection, suggesting that classical complement activation was not
generally elevated in the pulmonary compartment of Trem-22/2
mice following S. pneumoniae infection (Fig. S7).
We therefore studied the potential direct contribution of C1q to
bacterial phagocytosis, and pre-incubated WT AM with C1q or
control BSA and quantified the uptake of S. pneumoniae. C1q
significantly increased bacterial phagocytosis by AM (Fig. 5A),
thus confirming a direct role for C1q in phagocytosis, independent
of complement activation. Further, these data are consistent with
data, showing that C1q can bind to S. pneumoniae, independent of
IgG and increase internalization [52]. As our data indicated that
PPAR-d activation enhanced C1q levels in WT AM (Fig. S5) and
that PPAR-d inhibition could lower C1q levels (Fig. 4F), we next
decided to examine the role of PPAR-d mediated C1q production
in the context of S. pneumoniae phagocytosis within WT AMs. AMs,
where PPAR-d had been inhibited exhibited lower S. pneumoniae
uptake compared to DMSO control cells. Importantly, the
attenuated S. pneumoniae phagocytosis upon PPAR-d inhibition
was increased to levels of DMSO control cells upon addition of
C1q (Fig. 5B). These data strongly suggest that in AM the
principal target for PPAR-d is C1q for the regulation of S.
pneumoniae phagocytosis. Given that PPAR-d inhibitors can lower
basal C1q production in Trem-22/2 AM (Fig. 4F and Fig. S5),
we next postulated that inhibiting C1q using PPAR-d inhibitors
would revert the enhanced phagocytosis by Trem-22/2 AM to WT
levels. Significantly, at the dose of inhibitor where C1qb transcript
levels in TREM-2 deficient AM were lowered to that of WT AM
(i.e. 10 mM GSK0660 (Fig. 4F)), phagocytosis was no longer
Figure 5. Enhanced phagocytosis by Trem-22/2 AM depends on C1q. (A) WT AM were adhered to C1q, control BSA or uncoated plates for 3 h
prior to incubation with FITC labeled S. pneumoniae (MOI 100) and phagocytosis was assessed using FACS 1 h later (n = 3–4 per condition). (B) WT AM
(n = 6–7 per condition) were pre-treated for 24 h with 10 mM PPAR-d inhibitor GSK0660 or DMSO control after which, the cells were adhered to C1q or
control plates for 3 h and phagocytosis of FITC labeled S. pneumoniae (MOI 100) was assessed 1 h later using FACS. (C) WT and Trem-22/2 AM (n = 4
per genotype/condition) were pre-treated for 24 h with the indicated doses of the PPAR-d inhibitor GSK0660 or DMSO control after which
phagocytosis of FITC labeled S. pneumoniae (MOI 100) was assessed 1 h later using FACS. (D) WT and Trem-22/2 AM were pre-treated for 1 h with
10 mg/ml C1q blocking antibody or isotype control and phagocytosis of FITC labeled S. pneumoniae (MOI 100) was assessed 1 h later using FACS
(n = 4 per genotype/condition). (E) WT and Trem-22/2 AM (n = 4–7 per condition) were adhered for 3 h to plates coated with the indicated conditions
prior to incubation with FITC labeled S. pneumoniae (MOI 100) and phagocytosis was assessed using FACS. (F) WT and Trem-22/2 AM (n= 4 per
genotype) were incubated with FITC labeled S. pneumoniae (MOI 100) that were pre-opsonised with 10% WT or C1qa2/2 serum for 30 min after
which phagocytosis was assessed 1 h later using FACS (G) WT and Trem-22/2 mice (n = 17 per condition) were intranasally treated with 125 mg C1q
blocking antibody or isotype control prior to infection with 66104 CFU S. pneumoniae. 48 h post infection lung bacterial CFUs were enumerated.
Data represent mean 6 SEM; ** p,0.005, *** p,0.001, **** p,0.0001. Data in (A, C–F) are representative of two independent experiments, (B and
G) are pooled data from two independent experiments.
doi:10.1371/journal.ppat.1004167.g005
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different between WT and Trem-22/2 AM (Fig. 5C). These data
linked elevated C1qb levels, produced in a PPAR-d dependent
manner, with enhanced phagocytosis. To confirm the dependence
of enhanced phagocytosis by Trem-22/2 AM on higher C1q levels,
we blocked C1q using a blocking antibody and discovered that
C1q blockage abolished any differences in phagocytosis between
WT and Trem-22/2 AM (Fig. 5D). To then test if exogenous
administration of C1q would enhance phagocytosis of WT AMs to
Trem-22/2 levels, we adhered WT AM to C1q coated plates and
quantified uptake of S. pneumoniae compared to Trem-22/2 AM.
Consistent with results in Fig. 5A, C1q enhanced phagocytosis of
S. pneumoniae by WT AM in a dose dependent manner to reach
Trem-22/2 levels (Fig. 5E). Thus, using two independent
approaches of inhibiting C1q in Trem-22/2 AM, as well as
exogenously supplementing C1q in WT AM, we demonstrated
that the enhanced phagocytosis of S. pneumoniae by Trem-22/2 AM
depended on macrophage derived C1q.
Bone marrow transplantation experiments indicate that trans-
plantation of WT bone marrow into C1qa2/2 mice restores levels
of serum C1q to WT, clearly demonstrating that C1q is produced
by myeloid cells [46]. To further ratify the importance of
macrophage derived C1q versus serum C1q, we next opsonised
S. pneumoniae with serum from WT or C1qa2/2 mice and examined
phagocytosis. Our hypothesis was that the difference in phagocy-
tosis between WT and Trem-22/2 AM would still be visible in the
presence of C1q-deficient serum, although overall phagocytosis
levels would be reduced in both genotypes. Indeed, this was the
case, strongly suggesting that AM are the source of C1q and that
elevated C1q levels produced by Trem-22/2 AM mediate the
enhanced phagocytosis of S. pneumoniae (Fig. 5F).
To finally study the importance of elevated C1q production by
Trem-22/2 AM in vivo, we blocked C1q in lungs of mice before
infection with S. pneumoniae and quantified bacterial clearance.
Indeed, blocking pulmonary C1q could reverse the difference in
bacterial counts between WT and Trem-22/2 animals (Fig. 5G).
We conclude that the improved bacterial clearance we observed in
TREM-2 deficient animals was intimately linked to enhanced C1q
production by TREM-2 deficient AM.
TREM-2 is deleterious during pneumococcal pneumonia
The enhanced bacterial phagocytosis of S. pneumoniae in Trem-
22/2 mice finally led us to monitor the survival of WT and Trem-
22/2 mice during pneumonia. Ninety five hours post infection,
before the first Trem-22/2 mouse succumbed, 60% of WT mice
were dead, demonstrating conclusively that WT mice displayed
enhanced mortality compared to their TREM-2 deficient coun-
terparts during pneumococcal pneumonia (Fig. 6A). To deter-
mine the reasons for this effect, we evaluated pulmonary bacterial
loads and bacteremia shortly before the first mouse succumbed.
TREM-2 deficient mice exhibited a thousand fold decrease in S.
pneumoniae burden in lungs 48 h post infection (Fig. 6B). These
data corroborated our earlier time points of infection (Fig. 3M).
However, although, we had observed that Trem-22/2 mice
reproducibly exhibit enhanced bacterial clearance compared to
WT mice (Fig. 3M, 5G and 6B), there were some differences in
the degree of bacterial clearance. Natural variation in animal
experiments or differences in experimental setup could explain
this. Strikingly, while seven out of nine WT mice exhibited
bacteremia, S. pneumoniae could only be detected in the blood of
one Trem-22/2 mouse (Fig. 6C). Elevated bacteremia in WT mice
resulted in enhanced systemic inflammation as determined by
plasma IL-6 measurements, compared to TREM-2 deficient mice
(Fig. 6D).
We next evaluated lung pathology and inflammation. Lung
histology revealed that the levels of interstitial inflammation,
pleuritis and edema formation were greatly decreased in mice
deficient for TREM-2 compared to WT mice (Fig. 6E and 6F).
In agreement with this, we detected diminished pulmonary
cytokine levels such as TNF-a, IL-1b, MCP-1 and IL-6 (Fig. 6G).
Attenuated pulmonary inflammation is not only associated with
decreased bacterial burden within the lungs but can also be
attributed to improved clearance of apoptotic neutrophils by AM,
which promotes the resolution of inflammation [53,54,55,56]. To
examine the possibility that the higher inflammation in WT mice
might be associated with more apoptotic cells, we monitored
pulmonary neutrophil infiltration and active caspase 3 levels in
WT and Trem-22/2 mice using Ly6G and active caspase 3
staining. We could observe that Trem-22/2 mice displayed
attenuated neutrophil and active caspase 3 levels, particularly in
the interstitial space, 48 h post S. pneumoniae infection (Fig. 6H,
6I). Elevated pulmonary cell apoptosis of WT mice late during
pneumococcal pneumonia was confirmed using TUNEL staining
(Fig. 6J). Specificity for all stainings was verified as no positive
signal was detected in the respective isotype controls (Fig. S8). We
next tested the hypothesis that aside from improved S. pneumoniae
phagocytosis (Fig. 3 and 5), Trem-22/2 AM may exhibit elevated
apoptotic cell uptake, also known as efferocytosis. To model this
we measured the uptake of CFSE labeled apoptotic thymocytes, a
well-established and widely used method for determining effer-
ocytosis. Thymocyte apoptosis was confirmed using both DNA
laddering and Annexin V/7-AAD positivity (Fig. 6K and L).
While there was no difference in the clearance of CFSE labeled
apoptotic bodies at low doses between the genotypes of AM,
importantly, at a MOI of 10, Trem-22/2 AM exhibited
significantly elevated efferocytosis compared to WT AM
(Fig. 6M).
We conclude that TREM-2 deficiency improved bacterial and
apoptotic cell clearance, lung pathology and prevented systemic
inflammation during pneumococcal pneumonia, all of which
ultimately led to improved survival.
Discussion
In this study we examined the effects of TREM-2 on bacterial
phagocytosis and pulmonary inflammation within the context of
bacterial pneumonia. We unexpectedly discovered a cell-type
specific role for TREM-2, as TREM-2 suppresses bacterial
phagocytosis via repression of C1q in AM. These findings
demonstrate a previously unknown link between ITAM associated
receptor expression and opsonin production in resident AM and
explains the detrimental function of TREM-2 during pneumo-
coccal pneumonia.
C1q is a member of the defense collagen family that is
important for initiating the classical complement pathway and
thereby crucial for host defense against pneumococci [30,50,57].
C1q consists of 18 polypeptide chains that associate together in a
‘‘bouquet of tulips’’ like configuration, with each C1q chain
containing a C-terminal globular region that recognizes PAMPs,
and a N-terminal collagenous region that associates with
phagocytic receptors on macrophages to enhance bacterial
phagocytosis [45,51]. Within the pulmonary compartment, C1q
is produced locally by AM [45,46], i.e. by those cells that provide
the first phagocytic line of defense against S. pneumoniae [29,39].
C1q has been shown to act as a molecular bridge between S.
pneumoniae and host cells, independently of IgG and serotype,
facilitating increased adherence and bacterial uptake [52]. Our
data reveal a previously unknown link between C1q and TREM-2
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and suggest that TREM-2 suppresses C1q production by AM via a
mechanism that involves PPAR-d associated pathways (Fig. 4).
The consequence of this suppressive effect by TREM-2 in AM is
important as it explains the detrimental impact of TREM-2 during
pneumococcal pneumonia. Our findings that blocking the locally
enhanced production of pulmonary C1q was sufficient to reverse
the improved bacterial clearance by Trem-22/2 AM in vivo and in
vitro support this argument (Fig. 5).
Beside AM, neutrophils are considered important in phagocy-
tosing bacteria upon lung infections and since we observed a
modest increase in neutrophil influx early during pneumococcal
pneumonia in Trem-22/2 mice, these cells could contribute to the
enhanced bacterial clearance in these mice. Although we cannot
exclusively rule out this possibility, we importantly discovered that
neutrophils from TREM-2 deficient mice exhibit a tendency
towards lower uptake of S. pneumoniae in vivo, while Trem-22/2 AM
exhibit increased phagocytosis in vitro and in vivo (Fig. 3).
Underscoring the importance of AM in bacterial clearance during
pneumonia over neutrophils, previous studies by our group show
that selective changes in KC secretion and neutrophil influx
occurring in a TLR2 dependent manner are not sufficient to
induce altered bacterial clearance or differences in outcome during
pneumococcal pneumonia in vivo [58].
But how does TREM-2 influence C1q production? PPARs are
nuclear receptors that are ligand inducible transcription factors
and activate target genes through binding to PPAR-response
elements (PPREs) as heterodimers with the retinoid X receptor
family [59]. PPARs shuttle between the cytoplasm and nucleus in
response to ligand activation [60]. Three lines of evidence link
PPAR-d to the enhanced C1q production in AM: 1) PPAR-d
activation enhances production of C1q by AM; 2) PPAR-d
inhibition lowers levels of C1q in Trem-22/2 AM to WT AM; 3)
Over-expression of TREM-2 lowers levels of C1q and PPAR-d
activation. Interestingly the early ligand induced activation kinetics
and nuclear shuttling of PPAR-d are elevated in Trem-22/2 AM,
while PPAR-d appears to be primarily localized in the cytoplasm
of WT AM (Fig. 4I). These data suggest that the manner by
which TREM-2 influences C1q transcription is mediated by
effects on PPAR-d activation, possibly via interference with PPAR-
d ligand binding, as already suggested by our PPRE reporter
experiments and activity assays (Fig. 4G and H). Regardless of
the exact mechanism whereby TREM-2 inhibits PPAR-d activity,
our data suggests that C1q is the principal target for PPAR-d in
the regulation of S. pneumoniae phagocytosis within AM (Fig. 5B–
C).
Our observations of enhanced phagocytosis in TREM-2
deficient AM are important as they raise awareness of conceptu-
ally labeling ‘‘TREM-2 as a phagocytic receptor for bacteria.’’ We
do not dispute previous studies showing that TREM-2 deficiency
in BMDM leads to lower bacterial phagocytosis [21]. In fact, we
were able to reproduce these findings but believe that the effects of
TREM-2 on phagocytosis are cell-type specific. While AM and
BMDM are related cell types, they present substantial differences
with the former cell type being a resident macrophage isolated
using lavage and the latter isolated from bone marrow and in vitro
differentiated with M-CSF. Although differential C1q expression
upon TREM-2 deficiency may account for the phagocytic
differences between the cell types, it is highly likely that in
BMDM, additional factors play a role.
The cell-type specific effects of TREM-2 on phagocytosis are
reminiscent of its effects on antigen presentation and osteoclasto-
genesis, which clearly differ between different cell types. TREM-2
stimulation of immature dendritic cells induces expression of
MHC class II and co-stimulatory molecules that are required for
antigen presentation [61], but this effect is not observed in
microglia [11]. TREM-2 deficiency in RAW 264.7 macrophages
and human monocytes leads to a reduced capacity to generate
osteoclast precursors but bone marrow cells from Trem-22/2 mice
exhibit accelerated osteoclastogenesis [12,32,62]. Furthermore,
although TREM-2 has been shown to be a phagocytic receptor for
apoptotic neurons [11], uptake of microspheres is unchanged
following knockdown of TREM-2, indicating TREM-2 is not
essential for all types of phagocytosis [63].
Interestingly, our data show that AM expressed TREM-2 not
only suppresses bacterial phagocytosis but also efferocytosis
(Fig. 6M). These data are in contrast to previous studies
suggesting that TREM-2 promotes the uptake of apoptotic
neurons by microglia [11,63]. C1q is important for the uptake
of apoptotic cells [47,48,49]. Indeed, as C1qa2/2 mice age they
develop multiple apoptotic bodies and autoimmunity compared to
WT controls [47]. Within the lung, improved clearance of
apoptotic neutrophils by AM promotes the resolution of inflam-
mation [53,54,55,56]. Our data raise the intriguing possibility,
that AM expressed TREM-2 might influence efferocytosis through
C1q. This hypothesis is consistent with our observations of
TREM-2 specifically modulating bacterial phagocytosis and
efferocytosis but not the uptake of BSA by AM. These findings
make perfect sense in the context of TREM-2 modulating these
processes via C1q, as C1q acts as a bacterial opsonin and is also
critical for the uptake of apoptotic cells.
The ability of TREM-2 to regulate cellular responses in a cell-
type specific manner is not limited to phagocytosis and
efferocytosis. In this study we show that TREM-2 also modulates
S. pneumoniae and TLR2 induced inflammation in a cell-type
specific manner, with TREM-2 deficient AMs displaying less
inflammation in response to either stimulus. Importantly, these
observations are consistent with very recent studies by Correale et
al., who demonstrated that dendritic cells from Trem-22/2 mice
display attenuated inflammation in response to TLR ligands [64].
Further, we find in vivo that, other than KC, no other
inflammatory mediator tested was higher in Trem-22/2 mice
following early pneumococcal infection compared to their WT
counterparts. In this regard it is important to note that recent
observations indicate that the anti-inflammatory activity of
TREM-2 in vivo may differ depending on the disease context.
For example, Trem-22/2 mice exhibit attenuated inflammation
Figure 6. TREM-2 deficiency improves outcome during pneumococcal pneumonia. (A) WT and Trem-22/2 mice were intranasally infected
with 105 CFU S. pneumoniae and survival was monitored for 10 days (n = 13/genotype). (B–G) WT and Trem-22/2mice (n = 9 mice per genotype) were
intranasally infected with 16105 CFU S. pneumoniae and (B) lung bacterial CFUs were enumerated 48 h post infection. (C) Blood cultures were
monitored for S. pneumoniae (D), IL-6 levels were evaluated in the plasma using ELISA. (E) Representative H/E staining of lungs 48 h post infection. (F)
Lung inflammation score, as described in the Methods section. (G) Levels of lung cytokines were evaluated using ELISA. (H–J) Representative Ly6G
(H), active caspase 3 (I) and TUNEL (J) staining of lungs 48 h post infection. Magnification depicted for TUNEL stains is 206 and arrows indicate
caspase 3 positive cells. (K–L) Thymocytes (n = 4) were treated with 1 mM dexamethasone and apoptosis was evaluated using DNA laddering (K) or
Annexin-V/7-AAD positivity (L). (M) WT and Trem-22/2 AM (n= 8 per genotype and condition), were fed CFSE labeled apoptotic cells and
efferocytosis was assessed 1 h later using FACS. Data in B, D, F, G and M are presented as mean 6 SEM, WT versus TREM-22/2. Data in A–G are
representative of two independent experiments. Data in M is pooled data from 2 independent experiments; * p =,0.05, ** p= 0.005.
doi:10.1371/journal.ppat.1004167.g006
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following DSS induced colitis and stroke, rather than augmented
inflammation as expected [64,65]. In summary, our study,
together with others present in the literature, provides credence
for the claim that TREM-2 impacts cellular responses in a cell-
type, stimulus- and disease context-specific manner. Since we
found TREM-2 to suppress C1q secretion, it is interesting that
C1q has been shown to dampen TLR mediated cytokine synthesis,
although the exact mechanism behind this is unknown [66,67]. It
is tempting to speculate that the suppressive effects of TREM-2 on
C1q production in AM not only modulate bacterial phagocytosis
but also dampen TLR mediated inflammation.
This is the first report demonstrating a function for TREM-2 in
the pulmonary compartment. Importantly, we clearly show that the
ability of TREM-2 to confer bacterial phagocytosis is cell-type
specific and that TREM-2 modulates C1q production by AM. It is
tempting to speculate that targeting the TREM-2 pathway could be
used as a novel strategy for modulating C1q production and
pulmonary innate immune responses, whichmight be of relevance to
other respiratory tract infections and possibly autoimmune diseases.
Materials and Methods
ELISA and reagents
ELISA kits for mouse TNF, MCP-1, IL-1b, IL-6, KC and C5a
were from R & D Systems and the mouse C3a ELISA was from
Uscn Life Science Inc. All ELISAs were performed according to the
manufacturer’s instructions. GSK0660 was from Tocris Biochem-
icals. GW0742 and GSK3787 and recombinant C1q were
purchased from Sigma. S. pneumoniae LTA was a kind gift from
Sonja von Aulock (University of Konstanz, Germany). C1q
antibodies used for FACS and blocking experiments were clones
7H-8 (in vitro and in vivo) and JL-1 (in vitro) respectively, both
purchased from Hycult Biotech as was the MARCO (clone ED-31)
antibody. Isotype control antibody IgG2bk (559530) used for C1q
blocking experiments was from BD Bioscience. CD36 (clone 63)
antibody was from Millipore. CD45-V500 (clone 30-F11) was from
BD Bioscience. Ly6G-PE (clone 1A8), CD11c-APC (clone N418),
F4/80 (clone BM8) antibodies were from Biolegend. CD11b-Alexa
Fluor 700 (clone M1/70) was from eBioscience. TREM-2
(BAF1729), PPAR-d ab8937) and b-actin (clone AC15) antibodies
for western blotting were from R/D systems, AbCaM and Sigma
respectively. Recombinant PPAR-d was supplied in the PPAR-d
activity assay (Abcam ab133106). Ly6G (clone 1A8) and active
caspase 3 (Asp175 – clone 5A1E) antibodies used in IHC were from
BD Bioscience and Cell Signaling respectively. As secondary
reagents we used PE conjugated rat anti-mouse (eBioscience),
FITC conjugated goat anti-rat F(ab’)2 (Jackson Immunoresearch),
anti-rabbit HRP (Cell Signaling), streptavidin HRP (R/D systems),
anti-mouse HRP (BioRad), biotinylated anti-rat IgG (Vector
Laboratories) and biotinylated, swine anti-rabbit IgG (Dako) .
Animals
Trem-22/2mice were generated as previously described [10] and
the TREM-2 mutation was backcrossed onto a.98% B6 C57BL/6
background facilitated by genome-wide SSLP typing at 10 cM
intervals (done by the Speed Congenics Facility of the Rheumatic
Diseases Core Center). Wild type mice were purchased from
Charles River and all mice were bred at the Medical University of
Vienna Animal facility under pathogen free conditions. Age (8–10
week) and sex matched mice were used in all experiments.
Ethics statement
All animal experiments were discussed and approved through
the Animal Care and Use Committee of the Medical University of
Vienna and the Austrian Ministry of Sciences and were carried out
in strict accordance with Austrian law (Tierversuchsgesetz;
BMWF-66.009/0321-II/10b/2008).
Bacteria
S. pneumoniae serotype 3 was obtained from American Type
Culture Collection (ATCC 6303). Serotype 19A S. pneumoniae was
a clinical isolate from a patient suffering from severe invasive
pneumococcal disease and confirmation of the serotype was
provided by antibodies specific to the capsule (Statens Serum
Institute). Both strains were grown for 6 h to mid-logarithmic
phase at 37uC in Todd-Hewitt broth (Difco), harvested by
centrifugation at 4000 rpm for 15 min at 4uC, and washed twice
in sterile saline. S. pneumoniae serotype 3, was used for all in vivo
experiments and most in-vitro experiments (except Fig. 3H).
Bacteria were diluted in sterile saline to obtain an estimated
concentration of 105 CFU per 50 ml for intranasal inoculation of
mice. The true concentration was determined by growing serial
10-fold dilutions on sheep blood agar plates overnight.
Mouse model of pneumococcal pneumonia
Pneumonia was induced by intranasal administration of a
bacterial suspension containing 105 CFU S. pneumoniae (ATCC
6303) as described earlier [19,58,68]. Six, 24, or 48 h after
infection, mice were anesthetized with ketamine (Pfizer) and
sacrificed. Blood was collected in EDTA-containing tubes and
plated on blood agar plates to determine bacterial counts, plasma
was stored at 220uC. Whole lungs were homogenized at 4uC in 4
volumes of sterile saline using a tissue homogenizer (Biospec
Products), after which serial 10-fold dilutions in sterile saline were
plated on blood agar plates, left at 37uC and CFU were counted
16 h later. Remaining lung homogenates were incubated for
30 min in lysis buffer (containing 300 mM NaCl, 30 mM Tris,
2 mM MgCl2, 2 mM CaCl2, 1% Triton X-100, and pepstatin A,
leupeptin, and aprotinin (all 20 ng/ml; pH 7.4; Sigma-Aldrich)) at
4uC, centrifuged at 1500 g at 4uC, and supernatants were stored at
220uC until cytokine measurements were performed. Lungs for
histology were harvested 48 h post infection, fixed in 10%
formalin, and embedded in paraffin. Four-mm sections were
stained with H&E and analyzed by a pathologist blinded for
groups, who scored lung inflammation and damage as previously
described [19,58].
In separate experiments, bronchoalveolar lavage (BAL) was
performed 6 h and 24 h after infection by exposing the trachea of
mice through a midline incision, canulating it with a sterile 18-
gauge venflon (BD Biosciences) and instilling two 500 ml aliquots
of sterile saline. Approximately, 0.9 ml was retrieved per mouse.
Total cell numbers were counted using a hemocytometer (Tu¨rck
chamber); differential cell counts were done on cytospin prepara-
tions stained with Giemsa. BALF supernatant was stored at 2
20uC for cytokine measurements. In some experiments, to assess
survival, mice were intranasally infected with S. pneumoniae and
survival was monitored regularly for 10 days. In experiments
involving C1q blocking, 125 mg of C1q blocking antibody (kindly
provided by Admar Verschoor, Technical University of Munich)
or isotype control were intranasally instilled prior to S. pneumoniae
infection.
Immunohistochemistry and TUNEL staining
Paraffin embedded lungs from WT and Trem-22/2 mice were
deparaffinized in xylene and ethanol and subjected to antigen-
retrieval using citrate buffer pH 6.0 (Vector laboratories). There-
after endogenous peroxidase activity was blocked with 1.6% H2O2
in PBS. Following washing and blocking steps using 10% swine or
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rabbit serum (Vector laboratories) in PBS for the active caspase 3
(Cell signaling) and Ly6G (BD Biosciences) stains respectively,
sections were incubated either overnight at 4uC or 1 h room
temperature with the active caspase 3 diluted to 1:25 in swine
serum overnight and the Ly6G antibody diluted 1 in 50 in rabbit
serum. After washing, endogenous biotin and avidin sites were
blocked using the avidin biotin blocking kit (Vector laboratories).
Sections were washed, and incubated with either biotinylated anti-
rat IgG (Vector Laboratories) or biotinylated, swine anti-rabbit
IgG (Dako) for the Ly6G and active caspase 3 stains respectively.
Binding was visualized using the Vectastain ABC kit (Vector
laboratories) followed by either a step where the sections were
incubated with DAB conjugated to HRP (active caspase 3) or
Nova Red stain (Vector laboratories, Ly6G stain). Sections were
countered with hematoxylin, dehydrated and subjected to light
microscopy.
Tunnel stain was performed using the in situ cell death
detection kit, according to the manufacturer’s instructions (Roche
1684809). Briefly, paraffin embedded lungs from WT and Trem-
22/2 mice were deparaffinized in xylene and ethanol and
subjected to antigen-retrieval using Pronase E (Sigma). Following
washing and incubation with Tunnel reaction mix, nuclei were
stained using DAPI (Sigma). Slides were visualized under
fluorescence illumination (Zeiss, AxioImager.M2).
Cell isolation, culture and stimulations
AM were obtained by BAL from healthy WT or Trem-22/2
mice. Cells were resuspended in RPMI 1640 containing 1%
penicillin/streptomycin (pen/strep) and 10% FCS and plated for
either phagocytosis assays or stimulations at the appropriate
density. In some cases this was on C1q (Sigma-Aldrich) coated or
BSA coated plates and cells were left to adhere for 3 h or
overnight before stimulations. BMDMs were retrieved from the
tibia and the femur of mice and differentiated in RPMI 1640
supplemented with 1% pen/strep, 10% FCS and 10% L929-
conditioned medium for 7 days.
Primary lung epithelial cells were isolated as previously
described [69] and were cultured in in HITES media as were
MLE-12 and 15 cells as previously described [31]. RAW 264.7
cells cultured in RPMI 1640 containing 1% pen/strep and 10%
FCS. In all experiments related to cytokine production cells were
stimulated with 26107 CFU/ml S. pneumoniae (MOI 100) or
10 mg/ml LTA for 6 h unless otherwise indicated.
Generation of TREM-2 over expressing RAW 264.7 cells
Retroviral transfection was used to generate RAW264.7 cells
that were stably transfected with GFP or TREM-2. Briefly, the
packaging cell line GP-293 HEK (Clontech) was transfected with
TREM-2 expression plasmid (pORF-mTREM-2 originally pur-
chased from InvivoGen) or GFP control plasmids and VSV-G
(retroviral vector). RAW 264.7 cells were infected with the virus
containing supernatants from HEK cells and successfully trans-
fected, GFP expressing cells were sorted by flow cytometry.
Luciferase assays
For reporter gene assays, HEK cells seeded at 1.56105cells/ml,
were transfected with PPRE luciferase promoter constructs
(provided by Nikolina Papac, Medical University of Vienna),
expression vectors encoding PPAR-d, RXR-a (provided by Ajay
Chawla, University of California, San Francisco), vector control
(pIRES, Stratagene) or a combination of PPAR-d, RXR-a
together with TREM-2 and DAP-12 (subcloned into the pIRES
backbone) using calcium phosphate. 24 h post transfection, cells
were stimulated with 1 mM GW0742 and 48 h post transfection
luciferase activity was determined using the Dual-Luciferase
Reporter Assay System according to the manufacturer’s instruc-
tions (Promega). All transfectants contained the pRenilla luciferase
gene vector (Promega) as an internal control for transfection
efficiency and luciferase values were normalized to renilla.
Preparation of FITC labeled bacteria and CFSE labeled
apoptotic cells
S. pneumoniae (ATCC 6303 and serotype 19A) or E.coli (018:K1)
were grown in Todd-Hewitt broth (Difco) or Luria Bertani
medium respectively, washed twice and resuspended in saline at a
concentration in the range of 109 CFU/ml as determined by
OD600. Bacteria were heat killed at 65uC, for 30 min, washed
once with 10 ml 0.1M NaHCO3, resuspended in a solution
containing 0.2 mg/ml FITC dissolved in 0.1M NaHCO3 and
incubated under constant stirring in the dark at 37uC for 1 h.
Bacteria were washed twice with PBS and the concentration was
set to obtain 26109 CFU/ml.
Thymocytes were isolated from 4 week old C57BL/6 female
mice and apoptosis was induced by culturing 66106 freshly
isolated thymocytes in RPMI/10% FCS with 1 mM dexametha-
sone for 16 h as previously described [70]. Apoptotic laddering
was assayed using a commercially available kit (Roche Diagnos-
tics). 7-AAD/Annexin V staining was performed by resuspending
the thymocytes in staining buffer (0.1M Hepes, 1.4M NaCl,
25 mM CaCl2, pH 7.4), after which Annexin V (BD Biosciences)
was added at 1:20 for 15 min, following which 7-AAD
(eBioscience) was added at 1:50 for 15 min. Cells were analyzed
by flow cytometry (BD LSR Fortessa). Following apoptosis,
thymocytes were labeled with CFSE, according to the manufac-
turer’s instructions (Molecular Probes).
Phagocytosis and efferocytosis assays
AM or BMDM from WT and Trem-22/2 mice were plated at
0.56106/ml in 12-well microtiter plates (Greiner) and allowed to
adhere overnight. After washing steps, FITC-labeled heat-killed S.
pneumoniae or E. coli (O18:K1) was added in the presence of RPMI
for 1 h (MOI 100) at 37uC or 4uC (as a negative control),
respectively. Cells were treated with proteinase K at 50 mg/ml for
15 min at room temperature to remove adherent but not
internalized bacteria and subsequently placed on ice and washed.
In some experiments, bacteria were pre-opsonised with either 10%
pooled WT mouse serum, C1qa2/2 serum [47] or 10% Type III
capsular antibody (Statens Serum Institute, Denmark) in RPMI for
30 min before addition to the cells. Uptake was analyzed using a
flow cytometer (Beckton Dickinson FACScalibur). The phagocy-
tosis index of each sample was calculated: (mean fluorescence x %
positive cells at 37uC) minus (mean fluorescence x % positive cells
at 4uC).
Verification of phagocytosis results obtained via FACS was
conducted using confocal microscopy as previously described [68].
Briefly, AM plated at 36105 in 8 well chamberslides (Lab-Tek
Chamberslide system) were incubated with FITC-labeled heat-
killed S. pneumoniae at a MOI 100 for 1 h at 37uC. After washing
steps, lysosomes were stained with Lysotracker red and nuclei with
DAPI (Invitrogen), followed by visualization using confocal laser
scanning microscopy (LSM 510, Zeiss). The ratio of engulfed
bacteria (as determined by overlay of green bacteria and red
lysosomes) was quantified by an independent researcher from 300
counted cells per well and is expressed as percentage of cells that
contain bacteria.
For the in vivo phagocytosis assays WT and Trem-22/2 mice
were inoculated intranasally with 56106 CFU (MOI 10, assuming
56105 cells in a naı¨ve mouse) FITC-labeled S. pneumoniae. BALF
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was collected 4 h later, cells were resuspended in a PBS
supplemented with 1% FCS and antibodies against Ly6G,
CD11b, F4/80, CD11c and CD45 and incubated for 30 min.
After a washing step, cells were resuspended in PBS and analyzed
by flow cytometry (BD LSR Fortessa). AMs were identified as F4/
80+, CD11c+, Ly6G2, CD11b2 cells. Neutrophils were identified
as the Ly6G+, CD11b+, F4/802 and CD11c2 population. To
control for background FITC signals and non-specific binding of
bacteria, the % of FITC-positive CD452 cells (i.e. non-phagocy-
tosing cells) was subtracted from the % of FITC-positive CD45+
cells (i.e. containing phagocytosing cells).
For efferocytosis assays AM from WT and Trem-22/2 mice
were incubated with CFSE labelled apoptotic thymocytes at the
indicated MOI for 1 h at 37uC or 4uC (as a negative control),
respectively. AM were subsequently removed and stained using
APC conjugated CD11c antibody (clone N418, eBioscience).
Uptake was analyzed using a flow cytometer (Beckton Dickinson
FACScalibur). The efferocytosis index of each sample was
calculated: (mean fluorescence x % CD11c+ CFSE+ cells at
37uC) minus (mean fluorescence x % CD11c+ CFSE+ at 4uC).
RT-PCR
Trizol was used for RNA extraction from primary cells and
cDNA was converted using the Superscript III first strand
synthesis system as recommended by the supplier (Invitrogen).
RT-PCR was conducted according to the LightCycler FastStart
DNA MasterPLUS SYBR Green I system using the Roche Light
cycler II sequence detector (Roche Applied Science). Mouse gene-
specific primer sequences used are shown in supporting informa-
tion Table S1. All transcript levels studied were normalized to
HPRT.
Western blotting
56106 cells were treated as indicated in the figure legends and
whole cell extracts were prepared. Cells were washed once with
cold PBS, after which the cell pellet was solubilized and lysed in ice
cold whole cell extract buffer (20 mM Hepes pH 7.6, 400 mM
NaCl, 1 mM EDTA, 5 mM NaF, 500 mM Na3VO4, 25%
glycerol, 0.1% NP-40, 1 mM PMSF, 1 mM DTT, 0.1 mg/ml
aprotonin). Lysates were centrifuged at 14,000 rpm for 15 minutes
and stored at 280uC. Equal amounts of protein were separated by
electrophoresis on a 10% SDS polyacrylamide gel and transferred
to polyvinylidene difluoride (PVDF) membranes. Antibodies
specific for TREM-2 and PPAR-d were used at 1:1000 and b-
actin at 1:500. Immunoreactive proteins were detected by
enhanced chemiluminescent protocol (GE Healthcare).
PPAR-d activity assay
56106 cells were treated as indicated in the figure legends and
nuclear extracts were prepared by washing the cells with ice cold
PBS, followed by three washes in 1 ml of ice cold hypotonic buffer
(10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl) to induce
swelling. Thereafter, the pellet was resuspended in hypotonic
buffer supplemented with 0.1% Nonidet P-40 and incubated on
ice for 5 minutes to release nuclei. Subsequently, samples were
centrifuged at 4uC to pellet nuclei, the cytoplasmic fraction was
removed and the nuclear pellett resuspended in 50 ml of ice cold
high salt buffer (20 mM HEPES pH 7.9, 1.5 mM MgCl2,
420 mM NaCl, 25% glycerol) and incubated for 15 minutes at
4uC. Disrupted nuclei were centrifuged at full speed in a table top
centrifuge for 15 minutes at 4uC, after which the supernatant
(nuclear fraction) removed. PPAR-d DNA binding activity in
nuclear extracts was determined using the PPAR-d transcription
factor assay kit according to the manufacturer’s instructions
(Abcam). In brief, nuclear extracts were incubated on a 96 well
plate to which the PPRE consensus sequence was immobilized.
After binding and washing, PPAR-d activity within nuclear
extracts was detected using a PPAR-d specific antibody followed
by incubation with a secondary HRP conjugated antibody and
quantification using spectrophotometry. The specific OD was
calculated by subtracting the non specific binding wells (i.e. wells
where nuclear extract was absent), and normalized to protein
content.
Microarray
Isolated total RNA was purified using the RNeasy kit per
manufacturer’s instructions (Qiagen). Total RNA (200 ng) was
then used for GeneChip analysis. Preparation of terminal-labeled
cDNA, hybridization to genome-wide murine GeneLevel 1.0 ST
GeneChips (Affymetrix), and scanning of the arrays were carried
out according to manufacturer’s protocols. Affymetrix microarray
cell intensity files were combined, and expression was normalized
using the robust multi-array average algorithm [71], generating an
expression matrix. Identification of differentially regulated genes
was performed with significance analysis of microarrays as
described previously [72]; a false-discovery rate of 5% was
imposed. All data are deposited at Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/) and the accession ID is
GSE51378.
Statistical analysis
Data are presented as the mean 6 SEM. Comparisons between
groups was assessed using either T-test or ANOVA followed by
Tukey’s multiple comparisons analysis, where appropriate. Sur-
vival data was analyzed by Log rank (Mantel-Cox) test using
GraphPad Prism Software.
Supporting Information
Figure S1 TREM-2 deficient AM exhibit enhanced
phagocytosis of S. pneumoniae as determined by
confocal microscopy.WT and Trem-22/2 AM were incubated
with FITC labeled S. pneumoniae at an MOI of 100 and confocal
microscopy was conducted as described in the materials and
methods. Depicted are the original pictures. Magnification6100.
(PDF)
Figure S2 TREM-2 deficient BMDM exhibit lower
phagocytosis of E.coli. WT and Trem-22/2 BMDM (n= 5
per genotype) were incubated with FITC labeled E. coli at an MOI
of 100 and phagocytosis was assessed 1 h later by FACS. Data are
presented as mean 6 SEM versus WT, **** p,0.0001 and are
representative of two independent experiments.
(PDF)
Figure S3 No difference in surface expression of the
phagocytic receptors CD36 and MARCO between WT
and TREM-22/2 AM. Basal surface expression of CD36 and
MARCO in WT versus Trem-22/2 AMs as determined by FACS.
Green lines depict WT macrophages, pink Trem-22/2 macro-
phages and black represents isotype control antibody.
(PDF)
Figure S4 Overexpression of TREM-2 lowers C1qc
levels. C1qc basal levels were determined in GFP control or
TREM-2 overexpressing RAW 264.7 macrophages using RT-
PCR (n= 4 per condition). Data are presented as mean 6 SEM
and are representative of two independent experiments, ***
indicates p,0.001.
(PDF)
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Figure S5 Dependence of C1q expression in AMs on
PPAR-d. (A) WT AM (n= 3–4 per condition) were pre-treated for
24 h with the indicated doses of the PPAR-d activator GW0742 in
combination with the PPAR-d inhibitor GSK3787 along with a
DMSO control after which RT-PCR of C1qb and C1qc was
performed. (B) WT and Trem-22/2 AM (n= 4 per condition) were
treated with DMSO or the PPAR-d inhibitor GSK3787 after
which RT-PCR of C1qb and C1qc was performed. Data are
presented as mean 6 SEM and compared versus WT with * p,
0.05, ** p,0.005.
(PDF)
Figure S6 No difference in PPAR-d levels between WT
and TREM-22/2 AM. (A) PPAR-d basal expression was
determined in WT and Trem-22/2 AM using RT-PCR (n= 3–4
per genotype). (B) PPAR-d protein levels from whole cell extracts
of WT and Trem-22/2 AM. The specificity of the antibody was
indicated by recombinant PPAR-d (rPPAR-d). Data are represen-
tative of two independent experiments.
(PDF)
Figure S7 Unaltered C3a and C5a levels in the BALF of
TREM-22/2mice following S. pneumoniae infection.WT
and Trem-22/2 mice (n= 6–7 mice per genotype) were intranasally
infected with 105 S. pneumoniae and C3a and C5a levels were
determined in the BALF 6 and 24 h post infection. Data represent
mean 6 SEM versus WT.
(PDF)
Figure S8 Specificity of antibodies used in Immunohis-
tochemistry and TUNEL. Representative Ly6G, active caspase
3, and TUNEL staining of lungs 48 h post infection of mice
infected with 105 S. pneumoniae (n = 9) depicting the specificities of
the antibodies used.
(PDF)
Table S1 Sequences of primers used for RT-PCR.
(DOCX)
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